Induction Chemotherapy with XXXX and @entity1487 in Advanced @entity135 : A Short Term Response Evaluation.

@entity1 @entity135 @entity137 @entity417 @entity5 @entity957 @entity900 @entity1544 @entity1487 @entity1210
BACKGROUND: Considering the uprising number of @entity135 in the state with limited options of medical and surgical treatment, the focus of this study involved on chemotherapy in advanced @entity135 . The aim of this study was to evaluate the efficacy and @entity137 of combination of @entity900 and @entity1487 (PF) as induction chemotherapy in @entity1 in locally advanced @entity1544 of @entity135 . MATERIALS AND METHODS: Forty four @entity1 with previously untreated stage III -IV advanced and inoperable cases were included in this prospective study. Induction chemotherapy consisted of 3 cycles of @entity900 100mg/mt(2) as infusion on day 1, @entity1487 of 750mg/mt(2) on day 2, @entity1487 of 1000mg/mt2 as infusion on day 3 in an inpatient basis. Cycles were repeated with an interval of 21 days. @entity1 were evaluated within a period of 3 weeks at the end of completion of third cycle of chemotherapy. Post chemotherapy local therapy was individualized based on the response, site and stage of the @entity5 . RESULTS: Out of 44 eligible and evaluable @entity1 , major dominance was noted in male group constituting 68%. After induction chemotherapy 58.8% of stage III experienced stable response, _ 44% had partial response. In stage IV, 44% showed a stable response and 33.3% had partial response. But in comparison to primary @entity5 response and nodal response, which had a significant clinical response, the overall response of malignancy with respect to stage and site specificity was clinically insignificant. Moderate adverse reaction was noted in 47.6% and 42.1% had mild reactions. Majority of @entity1 experienced grade 3 adverse events, of which @entity417 in females and @entity1210 in males pre-dominated. CONCLUSION: With the use of @entity900 and @entity1487 as induction chemotherapy agents in advanced and inoperable @entity957 of @entity135 , a distinct benefit was seen in stabilizing the @entity5 from progression. But achieving a significant complete response to the same is of faint possibility. An alternate multidrug regimen or multimodality treatment would be ideal to gain the optimum results from induction agents. @entity137 related to chemotherapy usually is transient at therapeutic doses, and can be controlled by adequate prophylactic measures.
